
SRI-31255 is an orally active LRRK2 ингибитор с IC50 values of 520 and 427 nM for human wild-type (WT) and mutant G2019S, respectively. SRI-31255 exerts neuroprotective effects by связывание to the ATP-связывание pocket of LRRK2, inhibiting киназы activity. SRI-31255 can be used as a lead compound for the development of LRRK2-targeted drugs for the treatment of Parkinson's disease.
SRI-31255 is an orally active LRRK2 inhibitor with IC50 values of 520 and 427 nM for human wild-type (WT) and mutant G2019S, respectively. SRI-31255 exerts neuroprotective effects by binding to the ATP-binding pocket of LRRK2, inhibiting kinase activity. SRI-31255 can be used as a lead compound for the development of LRRK2-targeted drugs for the treatment of Parkinson's disease.
Вращайте мышью · Колесо — масштаб
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.